Showing 3721-3730 of 5002 results for "".
- Cynosure Acquires Assets of RF Medical Device Manufacturer Ellman International, Inc.https://practicaldermatology.com/news/20140910-cynosure_acquires_assets_of_rf_medical_device_manufacturer_ellman_international_inc/2459121/Cynosure, Inc., which specializes in laser- and light-based aesthetic treatments for non-invasive and minimally invasive applications, has acquired the assets of Ellman International, Inc. for approximately $13.2 million in cash. In addition, Cynosure assumed certain contractual and current liab
- Dermira Completes $51 Million Financing and Expands Management Team and Board of Directorshttps://practicaldermatology.com/news/20140821-dermira_completes_51_million_financing_and_expands_management_team_and_board_of_directors/2459139/Dermira, a specialty biopharmaceutical focused on dermatology, completed a $51 million Series C financing. Existing investors Bay City Capital, New Enterprise Associates (NEA), Canaan Partners and UCB S.A. were joined by new investors Apple Tree Partners, Aisling Capital, Rock S
- Valeant Pharmaceuticals Announces Planned Management Departurehttps://practicaldermatology.com/news/20140616-valeant_pharmaceuticals_announces_planned_management_departure/2459206/Valeant Pharmaceuticals International, Inc. ("Valeant") (NYSE: VRX) (TSX: VRX) today announced that Ryan Weldon, Valeant's Executive Vice President and Company Group Chairman, will be leaving the Company following the divestiture of all rights to Restylane, Perlane, Emervel, Sculptra, and Dysport ow
- Foamix Establishes U.S. Subsidiary and Strengthens Executive Management With Appointment of Senior U.S. Leadership Teamhttps://practicaldermatology.com/news/20140611-foamix_establishes_us_subsidiary_and_strengthens_executive_management_with_appointment_of_senior_us_leadership_team/2459209/Foamix Pharmaceuticals, a clinical-stage, specialty pharmaceutical company focused on the development, patenting and commercialization of proprietary topical foams to address unmet needs in dermatology, today announced the establishment of its U.S. Subsidiary and appointment of five industry veteran
- Provectus Biopharmaceuticals Reaffirms Commitment to Bring PV-10 to Markethttps://practicaldermatology.com/news/20140528-provectus_biopharmaceuticals_reaffirms_commitment_to_bring_pv-10_to_market/2459229/The FDA will not to give PV-10 breakthrough therapy designation for treatment of patients with locally advanced cutaneous melanoma, because the data did not prove substantial over existing therapies. However, Provectus Biopharmaceuticals says it is still committed to bringing the investigational
- Free Drug Samples May Influence Prescribing Habitshttps://practicaldermatology.com/news/20140417-free_drug_samples_may_influence_prescribing_habits/2459266/Results of a study published online on April 16 in JAMA Dermatology found that the availability of free medication samples in dermatology offices appears to change pr
- Syneron Receives FDA Clearance to Market the Ultrashape System for Fat Cell Destructionhttps://practicaldermatology.com/news/20140414-syneron_receives_fda_clearance_to_market_the_ultrashape_system_for_fat_cell_destruction/2459273/
- Steroids Found to be Widely Prescribed by Dermatologists for Psoriasis Managementhttps://practicaldermatology.com/news/20140220-steroids_found_to_be_widely_prescribed_by_dermatologists_for_psoriasis_management/2459337/
- Oculus Innovative Sciences Receives European CE Mark for Use of Microcyn to Treat Mild to Moderate Acnehttps://practicaldermatology.com/news/20140204-oculus_innovative_sciences_receives_european_ce_mark_for_use_of_microcyn_to_treat_mild_to_moderate_acne/2459350/
- Merz Makes Offer for Obagihttps://practicaldermatology.com/news/20130402-merz_makes_offer_for_obagi/2459576/With an unexpected $383.5 million bid, Merz Pharma Group formally proposed to acquire Obagi Medical Products, outdoing rival Valeant's bid for Obagi announced late last month and reported in yesterday's edition of DermWire. Merz sent a letter to Obagi Medical Products Inc.'s board offering to buy al